CD19 and Sepsis: In line with imbalanced rates of lethal sepsis (Supplementary Table 8), representing the fulminant release of cytokines from the immune system, and distinct expression profiles for CD19- non-malignant immune cells (Fig. 4f), differential treatment efficacy for the addition of rituximab strongly supports a heterogeneous responsiveness of the immune system in identified biological subgroups.